Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zavegepant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL known ✓ | Q16602 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CALCA | P06881 | 16/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zavegepant SCHEMBL29360253 | 1.00 | CALCRL (1.00) | CALCRLCYP3A4CALCA | |
| Zavegepant SCHEMBL23748834 | 1.00 | CALCRL (1.00) | CALCRLCYP3A4CALCA | |
| Zavegepant SCHEMBL29918913 | 1.00 | CALCRL (1.00) | CALCRLCYP3A4CALCA | |
| Zavegepant SCHEMBL142472 | 1.00 | CALCRL (1.00) | CALCRLCYP3A4CALCA | |
| Zavegepant SCHEMBL29182146 | 0.99 | CALCRL (0.99) | CALCRLCYP3A4CALCA | |
| Zavegepant SCHEMBL29918668 | 0.99 | CALCRL (0.99) | CALCRLCYP3A4CALCA | |
| SCHEMBL30763651 | 0.97 | CALCRL (0.95) | CALCRLCYP3A4CALCA | |
| SCHEMBL29161729 | 0.97 | CALCRL (0.95) | CALCRLCYP3A4CALCA | |
| SCHEMBL29161731 | 0.97 | CALCRL (0.95) | CALCRLCYP3A4CALCA | |
| SCHEMBL178848 | 0.93 | CALCRL (0.88) | CALCRLCYP3A4CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622968-B2 | Formulation for oral delivery of proteins, peptides and small molecules with poor permeability | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2026-05-12 | — | — | US | claimed |
| US-20240366618-A1 | CGRP Antagonists for Treating Trigeminal Neuralgia | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-11-07 | — | — | US | claimed |
| WO-2023064195-A1 | CGRP ANTAGONISTS FOR TREATING TRIGEMINAL NEURALGIA | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-04-20 | — | — | WO | claimed |
| WO-2023034467-A2 | CGRP ANTAGONISTS FOR TREATING SKIN CONDITIONS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-03-09 | — | — | WO | claimed |
| US-20220249468-A1 | FORMULATION FOR ORAL DELIVERY OF PROTEINS, PEPTIDES AND SMALL MOLECULES WITH POOR PERMEABILITY | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-08-11 | — | — | US | claimed |
| EP-3952900-A1 | FORMULATION FOR ORAL DELIVERY OF PROTEINS, PEPTIDES AND SMALL MOLECULES WITH POOR PERMEABILITY | R.P. Scherer Technologies, LLC (US) | 2022-02-16 | — | — | EP | claimed |
| CN-113966223-A | Formulations for oral delivery of proteins, peptides and small molecules with poor permeability | R·P·舍勒科技有限责任公司 | 2022-01-21 | — | — | CN | claimed |
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | claimed |
| WO-2020210722-A1 | FORMULATION FOR ORAL DELIVERY OF PROTEINS, PEPTIDES AND SMALL MOLECULES WITH POOR PERMEABILITY | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2020-10-15 | — | — | WO | claimed |
| EP-2552906-B1 | CGRP RECEPTOR ANTAGONIST | BRISTOL MYERS SQUIBB CO (US) | 2016-01-06 | — | — | EP | claimed |
| US-8481546-B2 | CGRP receptor antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-09 | — | — | US | claimed |
| EP-2552906-A1 | CGRP RECEPTOR ANTAGONIST | Bristol-Myers Squibb Company (US) | 2013-02-06 | — | — | EP | claimed |
| US-20120059017-A1 | CGRP Receptor Antagonist | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | claimed |
| WO-2011123232-A1 | CGRP RECEPTOR ANTAGONIST | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-06 | — | — | WO | claimed |
| US-12622968-B2 | Formulation for oral delivery of proteins, peptides and small molecules with poor permeability | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2026-05-12 | — | — | US | disclosed |
| US-20240408080-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | PFIZER IRELAND PHARMACEUTICALS | 2024-12-12 | — | — | US | disclosed |
| US-20240366618-A1 | CGRP Antagonists for Treating Trigeminal Neuralgia | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-11-07 | — | — | US | disclosed |
| WO-2011123232-A1 | CGRP RECEPTOR ANTAGONIST | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011123232-A1 | CGRP RECEPTOR ANTAGONIST | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011123232-A1 | CGRP RECEPTOR ANTAGONIST | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622968-B2 | Formulation for oral delivery of proteins, peptides and small molecules with poor permeability | CETP, LIPA, TAS2R40 | CALCRL 22/4885CYP3A4 3279/4885CALCA 63/4885 |
| US-20240366618-A1 | CGRP Antagonists for Treating Trigeminal Neuralgia | OPRL1, CALCRL, CALCR | CALCRL 2/4885CYP3A4 4474/4885CALCA 4/4885 |
| US-20220249468-A1 | FORMULATION FOR ORAL DELIVERY OF PROTEINS, PEPTIDES AND SMALL MOLECULES WITH POOR PERMEABILITY | CETP, LIPA, PNLIP | CALCRL 10/4885CYP3A4 4246/4885CALCA 15/4885 |
| US-20240408080-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | CALCA, CALCB, CALCRL | CALCRL 3/4885CYP3A4 3130/4885CALCA 1/4885 |
| US-20120059017-A1 | CGRP Receptor Antagonist | CALCRL, PTGIR, CALCR | CALCRL 1/4885CYP3A4 3127/4885CALCA 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.